CHAMPIONS ONCOLOGY INC (CSBR)
US15870P3073 - Common Stock
We assign a fundamental rating of 1 out of 10 to CSBR. CSBR was compared to 58 industry peers in the Life Sciences Tools & Services industry. CSBR may be in some trouble as it scores bad on both profitability and health. CSBR is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CSBR had negative earnings in the past year.
CSBR had a negative operating cash flow in the past year.
In multiple years CSBR reported negative net income over the last 5 years.
Of the past 5 years CSBR 4 years had a positive operating cash flow.
1.2 Ratios
CSBR's Return On Assets of -36.33% is on the low side compared to the rest of the industry. CSBR is outperformed by 84.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.33% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-4.23%
ROA(5y)-4.22%
ROE(3y)-34.73%
ROE(5y)-27.12%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CSBR has a Gross Margin (40.09%) which is in line with its industry peers.
In the last couple of years the Gross Margin of CSBR has remained more or less at the same level.
CSBR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 40.09% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.62%
GM growth 5Y-1.15%
2. Health
2.1 Basic Checks
CSBR does not have a ROIC to compare to the WACC, probably because it is not profitable.
CSBR has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, CSBR has more shares outstanding
There is no outstanding debt for CSBR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -2.60, we must say that CSBR is in the distress zone and has some risk of bankruptcy.
CSBR has a Altman-Z score of -2.60. This is amonst the worse of the industry: CSBR underperforms 84.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.6 |
ROIC/WACCN/A
WACC12.32%
2.3 Liquidity
A Current Ratio of 0.60 indicates that CSBR may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.60, CSBR is doing worse than 98.28% of the companies in the same industry.
CSBR has a Quick Ratio of 0.60. This is a bad value and indicates that CSBR is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.60, CSBR is not doing good in the industry: 98.28% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.6 | ||
| Quick Ratio | 0.6 |
3. Growth
3.1 Past
The earnings per share for CSBR have decreased strongly by -200.00% in the last year.
The Revenue has decreased by -8.30% in the past year.
CSBR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.63% yearly.
EPS 1Y (TTM)-200%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q11.11%
Revenue 1Y (TTM)-8.3%
Revenue growth 3Y18.81%
Revenue growth 5Y21.63%
Revenue growth Q2Q-5.88%
3.2 Future
The Earnings Per Share is expected to grow by 5.39% on average over the next years.
Based on estimates for the next years, CSBR will show a quite strong growth in Revenue. The Revenue will grow by 11.83% on average per year.
EPS Next Y-64.77%
EPS Next 2Y5.39%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-9.18%
Revenue Next 2Y-0.1%
Revenue Next 3Y8.98%
Revenue Next 5Y11.83%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CSBR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CSBR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.39%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for CSBR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CHAMPIONS ONCOLOGY INC
NASDAQ:CSBR (5/3/2024, 7:00:01 PM)
5.13
+0.26 (+5.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap69.72M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.33% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 40.09% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.84
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.6 | ||
| Quick Ratio | 0.6 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-200%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-64.77%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-8.3%
Revenue growth 3Y18.81%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y